R&D

Research and Development plays a key role in Polichem’s international activities and the company organisation. Because of this, a significant percentage of the annual turnover is re-invested in this area. We stand committed to developing and delivering innovative medicines and medical devices that respond to specific medical needs.

NAME INDICATION DEVELOPMENT PHASE
P-3058 Onychomycosis Pivotal Phase III and paediatric studies in EU
Pivotal Phase III and Paediatric study plan agreed with FDA
P-3073 Nail Psoriasis Pivotal Phase III in EU and Paediatric study plan agreed with EMA
FDA IND opened
P-3074 AGA (androgenetic alopecia) Pivotal Phase III in EU
P-3085 Psoriasis Phase II in EU
P-25730 Antimycotic Preclinical
NAVI Herpes Virus Preclinical

Please have a look at our publications.